Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad Statistics

Total Valuation

KLSE:DPHARMA has a market cap or net worth of MYR 1.26 billion. The enterprise value is 1.50 billion.

Market Cap	1.26B
Enterprise Value	1.50B

Important Dates

The last earnings date was Friday, May 16, 2025.

Earnings Date	May 16, 2025
Ex-Dividend Date	Mar 5, 2025

Share Statistics

KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has increased by 0.09% in one year.

Current Share Class	961.94M
Shares Outstanding	961.94M
Shares Change (YoY)	+0.09%
Shares Change (QoQ)	-0.17%
Owned by Insiders (%)	0.30%
Owned by Institutions (%)	71.41%
Float	450.08M

Valuation Ratios

The trailing PE ratio is 17.27 and the forward PE ratio is 13.48. KLSE:DPHARMA's PEG ratio is 0.69.

PE Ratio	17.27
Forward PE	13.48
PS Ratio	1.43
PB Ratio	1.77
P/TBV Ratio	1.89
P/FCF Ratio	14.40
P/OCF Ratio	11.03
PEG Ratio	0.69

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.78, with an EV/FCF ratio of 17.20.

EV / Earnings	20.61
EV / Sales	1.70
EV / EBITDA	9.78
EV / EBIT	13.27
EV / FCF	17.20

Financial Position

The company has a current ratio of 3.83, with a Debt / Equity ratio of 0.71.

Current Ratio	3.83
Quick Ratio	2.60
Debt / Equity	0.71
Debt / EBITDA	3.27
Debt / FCF	5.75
Interest Coverage	4.52

Financial Efficiency

Return on equity (ROE) is 10.48% and return on invested capital (ROIC) is 5.84%.

Return on Equity (ROE)	10.48%
Return on Assets (ROA)	5.22%
Return on Invested Capital (ROIC)	5.84%
Return on Capital Employed (ROCE)	9.42%
Revenue Per Employee	451,438
Profits Per Employee	37,306
Employee Count	1,957
Asset Turnover	0.65
Inventory Turnover	2.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.76% in the last 52 weeks. The beta is 0.74, so KLSE:DPHARMA's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	+4.76%
50-Day Moving Average	1.21
200-Day Moving Average	1.24
Relative Strength Index (RSI)	62.66
Average Volume (20 Days)	598,710

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:DPHARMA had revenue of MYR 883.47 million and earned 73.01 million in profits. Earnings per share was 0.08.

Revenue	883.47M
Gross Profit	320.56M
Operating Income	113.41M
Pretax Income	93.66M
Net Income	73.01M
EBITDA	150.41M
EBIT	113.41M
Earnings Per Share (EPS)	0.08

Balance Sheet

The company has 258.85 million in cash and 503.41 million in debt, giving a net cash position of -244.56 million or -0.25 per share.

Cash & Cash Equivalents	258.85M
Total Debt	503.41M
Net Cash	-244.56M
Net Cash Per Share	-0.25
Equity (Book Value)	711.75M
Book Value Per Share	0.74
Working Capital	561.75M

Cash Flow

In the last 12 months, operating cash flow was 114.27 million and capital expenditures -26.77 million, giving a free cash flow of 87.50 million.

Operating Cash Flow	114.27M
Capital Expenditures	-26.77M
Free Cash Flow	87.50M
FCF Per Share	0.09

Margins

Gross margin is 36.28%, with operating and profit margins of 12.84% and 8.26%.

Gross Margin	36.28%
Operating Margin	12.84%
Pretax Margin	10.60%
Profit Margin	8.26%
EBITDA Margin	17.02%
EBIT Margin	12.84%
FCF Margin	9.90%

Dividends & Yields

This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.31%.

Dividend Per Share	0.03
Dividend Yield	2.31%
Dividend Growth (YoY)	30.43%
Years of Dividend Growth	1
Payout Ratio	39.53%
Buyback Yield	-0.09%
Shareholder Yield	2.22%
Earnings Yield	5.79%
FCF Yield	6.94%

Stock Splits

The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.

Last Split Date	Sep 6, 2021
Split Type	Forward
Split Ratio	1.3333333333

Scores

KLSE:DPHARMA has an Altman Z-Score of 2.78. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.78
Piotroski F-Score	n/a